Anti-angiogenic Agents Plus Anti-PD-1 Antibodies for uHCC
Condition: Hepatocellular Carcinoma Intervention: Drug: Anti-angiogenic agents plus anti-PD-1/PD-L1 antibodies Sponsor: Shanghai Zhongshan Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials